Cargando…

P911: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY

Detalles Bibliográficos
Autores principales:	Shupo, F., Mason, N., Jones, E., Wayi-Wayi, G., Repasky, M., Franklin, M., Brazier, J., Zibelnik, N., Mukherjee, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429394/ http://dx.doi.org/10.1097/01.HS9.0000846516.09605.40

Ejemplares similares

PB2708: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY
por: Franklin, Matt, et al.
Publicado: (2023)

Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver survey
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
por: Shupo, Francis, et al.
Publicado: (2023)

IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) AS A MANIFESTATION OF POST-COVID-19 INFLAMMATORY SYNDROME
por: YAN, CHRIS, et al.
Publicado: (2022)

Genetic basis for iMCD-TAFRO
por: Yoshimi, Akihide, et al.
Publicado: (2020)

International definition of iMCD-TAFRO: future perspectives
por: Nishimura, Yoshito, et al.
Publicado: (2022)

Doxycycline Changes the Transcriptome Profile of mIMCD3 Renal Epithelial Cells
por: Jung, Hyun Jun, et al.
Publicado: (2021)

Increased mTORC2 pathway activation in lymph nodes of iMCD‐TAFRO
por: Phillips, Alexis D., et al.
Publicado: (2022)

Expression and Trafficking of the γ Subunit of Na,K-ATPase in Hypertonically Challenged IMCD3 Cells
por: Pihakaski-Maunsbach, Kaarina, et al.
Publicado: (2008)

Unexpected localization of AQP3 and AQP4 induced by migration of primary cultured IMCD cells
por: Rose, Ralph, et al.
Publicado: (2021)

Epoxyeicosatrienoic Acids Attenuating Hypotonic-Induced Apoptosis of IMCD Cells via γ-ENaC Inhibition
por: Wang, Luyun, et al.
Publicado: (2014)

Metabolic Phenotyping of Anks3 Depletion in mIMCD-3 cells - a Putative Nephronophthisis Candidate
por: Schlimpert, Manuel, et al.
Publicado: (2018)

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
por: Rossi, Jean-Francois, et al.
Publicado: (2021)

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

P1733: NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET
por: Mukherjee, S., et al.
Publicado: (2022)

Oxalate induces type II epithelial to mesenchymal transition (EMT) in inner medullary collecting duct cells (IMCD) in vitro and stimulate the expression of osteogenic and fibrotic markers in kidney medulla in vivo
por: Convento, Marcia, et al.
Publicado: (2019)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura
por: Sood, Ruchi, et al.
Publicado: (2013)

Idiopathic Multicentric Hyaline Vascular-Type Castleman Disease
por: Moutinho, Adelaide, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease
por: Nishikori, Asami, et al.
Publicado: (2022)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
por: Kosmidis, Christoforos S., et al.
Publicado: (2022)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

Multicentre evaluation of the Boehringer Mannheim/Hitachi 911 Analysis System
por: Zaman, Z., et al.
Publicado: (1993)

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome
por: Ük, Ece, et al.
Publicado: (2022)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
por: Pierson, Sheila K., et al.
Publicado: (2022)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease
por: Arakawa, Akira, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)

Cutaneous plasmacytosis: A rare initial presentation of idiopathic multicentric Castleman's disease
por: Yamamoto, Yu, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease Presenting With Hypertensive Choroidopathy: A Case Report
por: Mimoto, Tamami, et al.
Publicado: (2023)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

Mac 911
por: Breen, Christopher
Publicado: (2002)

Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease
por: Chrysochoou, Stamatios, et al.
Publicado: (2022)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5psmffttnisuvhl9rgfbeoufln